Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

Rapamycin is used to prevent graft rejection in transplant recipients based on its ability to suppress T-cell proliferation. The drug blocks the activity of a protein known as mammalian target of ...

The mechanistic (or mammalian) target of rapamycin (mTOR) signaling pathway, implicated in rapid antidepressant effects, was investigated for its role in KNT-127's action. The researchers injected ...

The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than ...

Most recently, the mammalian target of rapamycin inhibitor rapamycin has been shown to decrease markers of SASP and oxidative stress in the experimental setting. In a 2019 randomized clinical ...